Abbott Laboratories
May 5, 2008
Eli Lilly, Abbott Labs execs hit FASB proposal
“Accumulating, summarizing and auditing this information will take more time than for any other current disclosure requirement”
Executives at Eli Lilly & Co. and Abbott Laboratories criticized FASB's proposal to require more detailed disclosure of the investment allocation and valuation of pension assets, calling it excessive and ... via Pensions & Investments
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
| Topic | Updated | Last By | Comments |
|---|---|---|---|
| Abbott profit beats Wall Street estimates for 2Q | Fri | Qamile Stema | 13 |
| FDA panel opposes Depakote warning | Jul 11 | Deeptoad | 1 |
| Sugar in popular Similac Organic baby formula r... | Jun '08 | Wendy | 5 |
| Mylan, Abbott settle anti-seizure drug dispute | Jun '08 | Jim | 1 |
| Abbott drugs in FDA risk reviews | Jun '08 | Corby | 2 |
| Arthritis drugs investigated for link to cancer | Jun '08 | RAG | 4 |
| Vacancies edging up for area's retailers -- Ban... | Jun '08 | speculator | 1 |
Most Popular
